Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael I. Halstead
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 100
- Beta
- 0.54
- Country
- CA
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 15.12
Financials
Revenue
$0.00-100.0%Net Income
$-101.36MEBITDA
$-102.71MFree Cash Flow
$-35.07MEPS (diluted)
$-1.39Shares Outstanding (diluted)
73.07M+20166.8%Operating Expenses
$102.71MCash & Debt
$170.57MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $-44.68M | $-147.05M | $-4.23 |
| 2025 | $472.3K | $-113.14M | $-5.59 |
| 2024 | $0.00 | $-78.08M | $-9.41 |
| 2023 | $251.0K | $-47.49M | $-9.73 |
| 2022 | $167.8K | $-67.63M | $-15.36 |
| 2021 | $864.0K | $-32.22M | $-12.24 |
| 2020 | $0.00 | $-1.94M | $-1.48 |
| 2019 | $0.00 | $-101.0K | $-0.28 |
| 2018 | $0.00 | $-220.8K | $-0.69 |
| 2017 | $0.00 | $-127.0K | $-0.35 |
Valuation
HELPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (9)
- Newsdefenseworld.net·15d ago·Positive
Cybin Inc. (NASDAQ:HELP) Stock Has Average Target Price of $47.33 According to Brokerages Shares of Cybin Inc. (NASDAQ: HELP - Get Free Report) have been assigned an average rating of "Buy" from the six analysts that are currently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have issued ratings on the stock in
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT
View source ↗ - Newsglobenewswire.com·26d ago·Negative
…m base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development of novel serotonergic agonists (“NSAs”), today announced that co-founders Eric So and Paul Glavine have stepped down from their respective executive …
View source ↗ - Newsglobenewswire.com·38d ago·Negative
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
Helus Pharma to Host Investor Presentation on October 21, 2026 NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce that the Company will host an investor presentation on October 21, 2026.
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
Helus Pharma Announces Completion of Legal Name Change NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the Company's legal name has been changed from “Cybin Inc.” to “Helus Pharma Inc.” effective October 1, 2026. The name change was approved by shareholders at the Company'…
View source ↗ - Newsglobenewswire.com·61d ago·Neutral
…nces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on September 22, 20…
View source ↗ - Newsglobenewswire.com·96d ago·Negative
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board Former Intra-Cellular Therapies, Inc. (“Intra-Cellular”) executives bring complementary experience in organizational scale-up, central nervous system (“CNS”) drug development, regulatory approvals and commercialization
View source ↗ - Newsglobenewswire.com·100d ago·Neutral
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights - Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization -
View source ↗
Earnings
Fri, Feb 12(in 3 months)
Consensus estimate $-0.68 per share
Typical surprise -18.7% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 16$-1.41 vs $-0.67miss
- Fri, Aug 14$-0.91 vs $-0.80miss
- Tue, Jun 30$-0.96 vs $-1.04beat
- Fri, Feb 13$-0.99 vs $-0.53miss
- Thu, Nov 13$-1.39 vs $-0.74miss
- Wed, Aug 13$-1.10 vs $-0.96miss
Estimates and results for HELP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HELP officers and directors.
- Bought
- $39k
- Sold
- —
1 trade
0 trades
- Cavers Gregbought
20 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in HELP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
